Human mesenchymal stem cells do not differentiate into cardiomyocytes in a cardiac ischemic xenomodel

References

• Braunwald E., Pfeffer M. A. Ventricular enlargement and remodeling following acute myocardial infarction: mechanisms and management. Am J Cardiol 1991; 68: 1D–6
   Google Scholar
• Beltrami A. P., Urbanek K., Kajstura J., Yan S. M., Finato N., Bussani R., et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Eng J Med 2001; 344: 1750–7
   PubMed Web of Science ®Google Scholar
• Sakai T., Li R‐K., Weisel R. D., Mickle D. A., Jia Z. Q., Tomita S., et al. Fetal cell transplantation: a comparison of three cell types. J Thorac Cardiovasc Surg 1999; 118: 715–25
   PubMed Web of Science ®Google Scholar
• Taylor D. A., Atkins B. Z., Hungspreugs P., Jones T. R., Reedy M. C., Hutcheson K. A., et al. Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation. Nat Med 1998; 4: 929–33
   PubMed Web of Science ®Google Scholar
• Menasche P., Hagege A. A., Scorsin M., Pouzet B., Desnos M., Duboc D., et al. Myoblast transplantation for heart failure. Lancet 2001; 357: 279–80
   PubMed Web of Science ®Google Scholar
• Scorsin M., Hagege A., Vilquin J. T., Fiszman M., Marotte F., Samuel J. L., et al. Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function. J Thorac Cardiovasc Surg 2000; 119: 1169–75
   PubMed Web of Science ®Google Scholar
• Li R. K., Weisel R. D., Mickle D. A., Jia Z. Q., Kim E. J., Sakai T., et al. Autologous porcine heart cell transplantation improved heart function after a myocardial infarction. J Thorac Cardiovasc Surg 2000; 119: 62–8
   PubMed Web of Science ®Google Scholar
• Tomita S., Li R. K., Weisel R. D., Mickle D. A., Kim E. J., Sakai T., et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999; 100((suppl II))II247–56
   Google Scholar
• Toma C., Pittenger M. F., Cahill K. S., Byrne B. J., Kessler P. D. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002; 105: 93–8
   PubMed Web of Science ®Google Scholar
• Min J. Y., Yang Y., Sullivan M. F., Ke Q., Converso K. L., Chen Y., et al. Long‐term improvement of cardiac function by transplantation of embryonic stem cell in post‐infarcted rats. J Thorac Cardiovasc Surg 2003; 125: 361–9
   PubMed Web of Science ®Google Scholar
• Pittenger M. F., Mackay A. M., Beck S. C., Jaiswal R. K., Douglas R., Mosca J. D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–7
   PubMed Web of Science ®Google Scholar
• Grinnemo K. H., Månsson A., Dellgren G., Klingberg D., Wardell E., Drvota V., et al. Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg 2004; 127: 1293–300
   PubMed Web of Science ®Google Scholar
• Guide for the care and use of laboratory animals. National Academy Press, Washington [DC] 1996, 140 pages
   Google Scholar
• Le Blanc K., Tammik L., Sundberg B., Haynesworth S. E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11–20
   PubMed Web of Science ®Google Scholar
• El Oakley R. M., Ooi O. C., Bongso A., Yacoub M. H. Myocyte transplantation for myocardial repair: a few good cells can mend a broken heart. Ann Thorac Surg 2001; 71: 1724–33
   PubMed Web of Science ®Google Scholar
• Rohwedel J., Guan K., Hegert C., Wobus A. M. Embryonic stem cells as an in vitro model for mutagenicity, cytotoxicity and embryo toxicity studies: present state and future prospects. Toxicol In Vitro 2001; 15: 741–53
   PubMed Web of Science ®Google Scholar
• Pittenger M. F., Mackay A. M., Beck S. C., Jaiswal R. K., Douglas R., Mosca J. D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–7
   PubMed Web of Science ®Google Scholar
• Mangi A. A., Noiseux N., Kong D., He H., Rezvani M., Ingwall J. S., et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003; 9: 1195–201
   PubMed Web of Science ®Google Scholar
• Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890–6
   PubMed Web of Science ®Google Scholar
• Klyushnenkova E., Mosca J. D., Zernetkina V., Majumdar M. K., Beggs K. J., Simonetti D. W., et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005; 12: 47–57
   PubMed Web of Science ®Google Scholar
• Le Blanc K., Gotherstrom C., Ringden O., Hassan M., McMahon R., Horwitz E., et al. Fetal mesenchymal stem‐cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005; 79: 1607–14
   PubMed Web of Science ®Google Scholar
• Liechty K. W., MacKenzie T. C., Shaaban A. F., Radu A., Moseley A. M., Deans R., et al. Human mesenchymal stem cells engraft and demonstrate site‐specific differentiation after in utero transplantation in sheep. Nat Med 2000; 6: 1282–6
   PubMed Web of Science ®Google Scholar
• Saito T., Kuang J. Q., Bi ttira B., Al‐Khaldi A., Chiu R. C. Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann Thorac Surg 2002; 74: 19–24
   PubMed Web of Science ®Google Scholar
• Le Blanc K., Rasmusson I., Gotherstrom C., Seidel C., Sundberg B., Sundin M., et al. Mesenchymal stem cells inhibit the expression of IL‐2 receptor (CD25) and CD38 on phytohemagglutinin activated lymphocytes. Scand J Immunol 2004; 60: 307–15
   PubMed Web of Science ®Google Scholar
• Rasmusson I., Ringdén O., Sundberg B., Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005; 305: 33–41
   PubMed Web of Science ®Google Scholar
• Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., et al. Treatment of severe acute graft‐versus‐host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439–41
   PubMed Web of Science ®Google Scholar
• Zhang Z., Bédard E., Luo Y., Wang H., Deng S., Kelvin D., et al. Animals models in xenotransplantation (review). Expert Opin Investig Drug 2000; 9: 2051–68
   PubMed Web of Science ®Google Scholar
• Aggarwal S., Pittenger M. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815–22
   PubMed Web of Science ®Google Scholar
• Murry C. E., Soonpaa M. H., Reinecke H., Nakajima H., Nakajima H. O., Tubart M., et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004; 428: 664–8
   PubMed Web of Science ®Google Scholar
• Nygren J. M., Jovinge S., Breitbach M., Sawen P., Roll W., Hescheler J., et al. Bone marrow‐derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 2004; 10: 494–501
   PubMed Web of Science ®Google Scholar